Scintimun (besilesomab)
- Region
- 🇪🇺 EU
- Active substance
- besilesomab
- Company
- Telix Innovations
- Status
- Authorised
- Therapeutic area
- Osteomyelitis; Radionuclide Imaging
- EU approval
- Mon 11 Jan 2010
- Application
- EMEA/H/C/001045
- ATC
- V09HA03
- Official record
- www.ema.europa.eu
Indication
This medicinal product is for diagnostic use only and the approved indication is scintigraphic imaging, in conjunction with other appropriate imaging modalities, for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis. Scintimun should not be used for the diagnosis of diabetic foot infection.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Scintimun Application withdrawn · CIS bio international
Follow Scintimun
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.